Materias dentro de su búsqueda.
Mostrando 2,261 - 2,280 Resultados de 2,516 Para Buscar '"National Cancer Institute"', tiempo de consulta: 0.30s Limitar resultados
  1. 2261
    “…Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study
  2. 2262
    “…IMPORTANCE: Increasing demand for cancer care may be outpacing the capacity of hospitals to provide timely treatment, particularly at referral centers such as National Cancer Institute (NCI)–designated and academic centers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation
  3. 2263
    “…METHODS: A prospective-longitudinal study was conducted among women with advanced epithelial ovarian cancer (AEOC), III and IV stages, and treated with NACT, at the National Cancer Institute – Mexico, from July 2017 to July 2018. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
  4. 2264
    “…Data on age-standardized incidence and mortality rates of gastric cancer among 48 countries were retrieved from the Surveillance, Epidemiology, and End Results Program, the National Cancer Institute, the Nordic Cancer Registries, and the World Health Organization Mortality Database. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Global Incidence and Mortality of Gastric Cancer, 1980-2018
  5. 2265
    “…OBJECTIVE: To examine differences in spending and utilization for patients with private insurance undergoing common cancer surgery at National Cancer Institute (NCI) centers vs community hospitals. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differences in Cancer Care Expenditures and Utilization for Surgery by Hospital Type Among Patients With Private Insurance
  6. 2266
    “…DATA SOURCES: Data on thyroid cancer incidence and mortality by sex among US adults (≥18 years) were extracted from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data for 1975 to 2017. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy
  7. 2267
    “…The dominant matchers achieve F1 measures of 0.9271, 0.8218, and 0.5 on Anatomy, FMA-NCI (Foundation Model of Anatomy-National Cancer Institute), and FMA-SNOMED data sets, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Matching Biomedical Ontologies: Construction of Matching Clues and Systematic Evaluation of Different Combinations of Matchers
  8. 2268
    “…Overall societal health care spending was estimated for each cancer type by multiplying the mean total spending per patient (estimated from MarketScan) by the number of privately insured patients living with that cancer in 2018, as reported by the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US
  9. 2269
    “…Toxicities were graded according to the National Cancer Institute’s Common Terminology Criteria V3.0. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
  10. 2270
    por Usher, C.M., Higgins, K.A.
    Publicado 2021
    “…We sought to quantify the differences in radiation consult volumes across varying disease sites and practice locations within our National Cancer Institute (NCI) designated Comprehensive Cancer Center, at time points preceding and during the COVID 19 pandemic. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of the COVID-19 Pandemic on Radiation Oncology Consult Volumes Within a Multi-Site Academic Practice
  11. 2271
    “…Therapeutic phase II and III NEN studies were identified through a database search of Medline (via PubMed), EMBASE (OvidSP), Cumulative Index of Nursing and Allied Health Literature (EBSCOhost), Web of Science (Clarivate), Cochrane Database of Systematic Reviews (Wiley), ClinicalTrials.gov (National Institutes of Health), EU Clinical Trials Register, and National Cancer Institute Clinical Trials. Data were analyzed between March and June 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
  12. 2272
    “…We aimed to describe disease characteristics and management in a large contemporary cohort of women with breast cancer at the National Cancer Institute of Sri Lanka (NCISL). METHODS: All women with invasive primary breast cancers diagnosed during 2016–2020 were identified from the NCISL breast cancer registry. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry
  13. 2273
    “…This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC
  14. 2274
    “…The primary endpoint was to evaluate the safety of HBV-TCR-T-cell therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) during the dose-escalation process. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
  15. 2275
    Publicado 2022
    “…FUNDING: Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities, St Baldrick's Foundation, and the National Cancer Institute.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
  16. 2276
    “…FUNDING: US National Cancer Institute, Wereld Kanker Onderzoek Fonds, and the IARC Environment and Lifestyle Epidemiology Branch. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alcohol consumption and oesophageal squamous cell cancer risk in east Africa: findings from the large multicentre ESCCAPE case-control study in Kenya, Tanzania, and Malawi
  17. 2277
    “…CONFLICT OF INTEREST DESCRIPTION: AD - CCTSI TOTTS TL1TR002533; SL - 18POST34030397 from the American Heart Association; AJ – no conflicts; KS - 1F31HL147393 from the National Heart, Lung, and Blood Institute, NIH; MM – no conflicts; RT – no conflicts; KSM – no conflicts; RAN - R01CA236222 from the National Cancer Institute, NIH, and 2018-03 from the Lungevity Foundation; and MCMW-E - R01 HL121877 from the National Heart, Lung, and Blood Institute, NIH, and 25A8679 from the Chernowitz Foundation.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    4369 Reprogramming of vascular smooth muscle cells to multipotent progenitor cells contributes to progression of atherosclerosis
  18. 2278
    por Karger, Amy B., Brien, James D., Christen, Jayne M., Dhakal, Santosh, Kemp, Troy J., Klein, Sabra L., Pinto, Ligia A., Premkumar, Lakshmanane, Roback, John D., Binder, Raquel A., Boehme, Karl W., Boppana, Suresh, Cordon-Cardo, Carlos, Crawford, James M., Daiss, John L., Dupuis, Alan P., Espino, Ana M., Firpo-Betancourt, Adolfo, Forconi, Catherine, Forrest, J. Craig, Girardin, Roxie C., Granger, Douglas A., Granger, Steve W., Haddad, Natalie S., Heaney, Christopher D., Hunt, Danielle T., Kennedy, Joshua L., King, Christopher L., Krammer, Florian, Kruczynski, Kate, LaBaer, Joshua, Lee, F. Eun-Hyung, Lee, William T., Liu, Shan-Lu, Lozanski, Gerard, Lucas, Todd, Mendu, Damodara Rao, Moormann, Ann M., Murugan, Vel, Okoye, Nkemakonam C., Pantoja, Petraleigh, Payne, Anne F., Park, Jin, Pinninti, Swetha, Pinto, Amelia K., Pisanic, Nora, Qiu, Ji, Sariol, Carlos A., Simon, Viviana, Song, Lusheng, Steffen, Tara L., Stone, E. Taylor, Styer, Linda M., Suthar, Mehul S., Thomas, Stefani N., Thyagarajan, Bharat, Wajnberg, Ania, Yates, Jennifer L., Sobhani, Kimia
    Publicado 2022
    “…BACKGROUND: In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and “to develop, validate, improve, and implement serological testing and associated technologies.” …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
  19. 2279
    “…PATIENTS AND METHODS: Stage IV colorectal cancer patients diagnosed between January 1, 2005 and December 31, 2015 were identified from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. To account for both measured and unmeasured confounders, the efficacy of PMTR and PTR in the left- and right-sided subgroups was evaluated using instrumental variable analysis, with the health service area as the instrument variable. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Primary tumor resection with or without metastasectomy for left- and right-sided stage IV colorectal cancer: an instrumental variable analysis
  20. 2280
    “…Within that framework, we mapped the concepts represented in the CDEs, and their possible values, into domain ontologies such as the Orphanet Rare Disease Ontology, Human Phenotype Ontology and National Cancer Institute Thesaurus. Finally, we created an exemplar, reusable ETL pipeline that we will be deploying over these non-coordinating data repositories to assist them in creating model-compliant FAIR data without requiring site-specific coding nor expertise in Linked Data or FAIR. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data
Herramientas de búsqueda: RSS